Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial / L. Rossi, C. Biagioni, A. Mccartney, I. Migliaccio, G. Curigliano, G. Sanna, E. Moretti, A.M. Minisini, S. Cinieri, C. Tondini, G. Arpino, A. Bernardo, A. Martignetti, E. Risi, M. Pestrin, L. Boni, M. Benelli, L. Biganzoli, A. Di Leo, L. Malorni. - In: BREAST CANCER RESEARCH. - ISSN 1465-5411. - 21:1(2019), pp. 71.1-71.7. [10.1186/s13058-019-1149-5]
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
G. Curigliano
;G. Sanna;
2019
Abstract
Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.File | Dimensione | Formato | |
---|---|---|---|
Updtate TREND.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
722.6 kB
Formato
Adobe PDF
|
722.6 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.